SGS Opens Three New Offices
SGS Opens Central & Eastern Europe Offices for Clinical Trial Management.
Geneva, Switzerland-April 25, 2008-As a further step in the initiative to expand its Global Clinical Development (GCD) services, SGS Life Science Services has opened three new offices in Poland, Czech Republic, and Romania. The offices located in Prague, Warsaw, and Bucharest, respectively, will provide services for clinical trial monitoring, study feasibility, and site selection, as well as support the regulatory aspects in these countries.
“The opening of the new offices addresses the request of many of our sponsors to conduct trials in Central and Eastern Europe in order to benefit from the vast pool of treatment naïve patients, faster enrolment times, and the cost benefits these countries offer,” said Luc Braeken, vice president of global clinical development. “Highly qualified and motivated investigators, low drop out rates of enrolled patients, and the high quality of the clinical data are additional advantages of conducting trials in Central and Eastern Europe.”
The offices are staffed with highly knowledgeable teams with broad experience in conducting clinical trials in the pharmaceutical and CRO industry as well as in academia. Lead by seasoned MDs, the teams cover a wide range of therapeutic areas with special emphasis in CNS, infectious disease, and cardiovascular disease, SGS’ areas of core expertise.Complementary services including project management, data management and statistics, regulatory affairs, and medical affairs will be provided from SGS’ main office for GCD in Belgium with more than 400 people.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
